Navigation Links
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
Date:7/22/2009

DEERFIELD, Ill., July 22, and OSAKA, Japan, July 23 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug Administration (FDA) that the FDA extended the review of the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS((R)) (pioglitazone HCl). The new Prescription Drug User Fee Act (PDUFA) date for the FDC is September 4, 2009.

The NDA for the FDC of alogliptin and ACTOS was submitted in September 2008, following the NDA submission of alogliptin monotherapy in December 2007. On March 6, 2009 the FDA informed Takeda that based on the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the amount of existing alogliptin clinical data in the alogliptin monotherapy NDA was not sufficient to meet certain statistical requirements outlined in that Guidance. On June 26, the FDA asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance for alogliptin.

About ACTOS((R)) (pioglitazone HCl)

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. ACTOS has not been studied in children and is not recommended for children under the age of 18. ACTOS may be taken alone or with a sulfonylurea, metformin, or insulin.

Important Safety Information About ACTOS

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause new, or worsen, heart fail
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... -- Research and Markets has announced ... Market 2014-2018" report to their offering. ... for software solutions, medical devices, imaging and diagnostic ... Medical Technologies market covers active implantable technology, hospital ... technology, dental technology, electromechanical medical technology, technical aids ...
(Date:9/12/2014)... DUBLIN , Sept. 12, 2014 ... "Global Animal Health Market 2014-2018" report to ... veterinary services intended to prevent animal diseases or treat ... lifetime, or increase the yield of animal food. The ... Additives, Pharmaceuticals, Vaccines, and Diagnostics. Animal feed additives improve ...
(Date:9/12/2014)... LONDON , Sept. 12, 2014 ... new disposable product ranges. The latest additions to ... congresses of the European Cataract and Refractive Surgeons ... The launches include Vitra™ Probes, ... Quantel Supra and Vitra™ laser systems. The laser ...
Breaking Medicine Technology:Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis 2Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis 3Quantel Medical Announces Addition Of Two New Disposable Products To Portfolio 2Quantel Medical Announces Addition Of Two New Disposable Products To Portfolio 3
(Date:9/14/2014)... (PRWEB) September 14, 2014 Globally the ... America, mainly in the US, followed by Europe and ... therapy centers and many are in development phase or ... in different countries as various governments are showing interest ... in Europe, mainly because of low awareness of this ...
(Date:9/14/2014)... Columbus, OH (PRWEB) September 14, 2014 A ... Wright & Schulte LLC on behalf of a Franklin ... DePuy metal-on-metal hip implant. The metal-on-metal hip lawsuit filed ... states that the Ohio man was 40 years old when ... hip. (Case No. 3:14-cv-02428-K) According to the hip ...
(Date:9/13/2014)... Over the past five years, ... Australia have shown signs of struggle. “The ... goods has caused Australian consumers to turn away ... IBISWorld industry analyst Ryan Lin. This trend has ... health consciousness, which has alerted the Australian population ...
(Date:9/13/2014)... MillionaireSinglesDating.com is a millionaire dating site ... dating services provider, which also launched the leading ... daddy site , SugarDaddyMeet.com, and the leading ... recently reached 2 million users milestone. , MillionaireSinglesDating.com ... include CEOs, lawyers, doctors, pro athletes, models and ...
(Date:9/13/2014)... September 13, 2014 Bedros Keuilian, founder of ... fitness marketing coach , has always been an advocate of ... most useful days are over, but the post explains that ... need to change. , “A lot of people think of ... says Keuilian. “They run a special and the only thing ...
Breaking Medicine News(10 mins):Health News:Global Proton Therapy Market Trends and 2018 Opportunities Now Available at MarketReportsOnline.com 2Health News:Global Proton Therapy Market Trends and 2018 Opportunities Now Available at MarketReportsOnline.com 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 4Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 5Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:MillionaireSinglesDating.com Reaches 2 Million Users Milestone 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 3
... for Research in Vision and Ophthalmology is honored to ... of ARVO Fellow recognizes members for their accomplishments, leadership ... this honor, ARVO anticipates that Fellows will continue to ... careers in vision and ophthalmology research and to further ...
... ... concerned with the pathogenesis of disease at the molecular level, in order to design ... ... time a person experiences symptoms of an aggressive brain tumor it is often too ...
... ALS ( Lou Gehrig,s disease) named Service Related Disorder Earlier ... In recognition of multiple studies connecting ALS to military ... December 22, 2009 , provided for the grant of ... Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig,s disease).  Deemed a ...
... , , DETROIT , ... today announced that its Board of Directors has set the date for ... for shareholders eligible to vote at the meeting.   , The Annual ... at 10:30 am EST at the MGM Grand Hotel, 1777 ...
... cuts that risk significantly, study finds , TUESDAY, Jan. 12 ... increase in resting heart rate boosts the risk of dying ... has found. , Norwegian researchers tracked the health of about ... of 18 years. During that time, 6,033 men and 4,442 ...
... Frank conversations about hospice and preferred place of death are ... -- Terminally ill patients have much to consider, from whether ... to whether they want doctors to continue aggressive treatment or ... months. , Yet those difficult, emotional conversations aren,t happening nearly ...
Cached Medicine News:Health News:ARVO announces 2010 fellows 2Health News:ARVO announces 2010 fellows 3Health News:ARVO announces 2010 fellows 4Health News:News from the Latest Issue of Molecular Medicine 2Health News:ALS Therapy Development Institute Receives $1.6 Million Grant From the Department of Defense for Lou Gehrig's Disease Research 2Health News:ALS Therapy Development Institute Receives $1.6 Million Grant From the Department of Defense for Lou Gehrig's Disease Research 3Health News:ALS Therapy Development Institute Receives $1.6 Million Grant From the Department of Defense for Lou Gehrig's Disease Research 4Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 3Health News:Faster Heart Rate May Raise Risk of Heart Attack Death 2Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 2Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 3
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: